January 22, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Gilead Sciences, Galapagos Close $2 Billion Deal for Anti­Infla

Source URL: www.dcat.org

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

Source URL: www.aidshealth.org

• Gilead Sciences
• Chemistry
• HIV/AIDS
• Medicine
• Organofluorides
• Specialty drugs
• Prodrugs
• Prevention of HIV/AIDS
• AIDS Healthcare Foundation
• Tenofovir alafenamide
• Tenofovir disoproxil
• Fixed-dose combination

March 4, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. Sponsored By:

Source URL: www.dcat.org

• Business
• Economy
• Health care
• Gilead Sciences
• Specialty drugs
• Pharmaceuticals policy
• Tenofovir alafenamide
• Valeant Pharmaceuticals
• Tenofovir disoproxil
• Rilpivirine
• Pharmaceutical industry in China
• AstraZeneca

Microsoft Word - GILEAD BRIEFING

Source URL: www.ukts.org

• Health
• Medicine
• Breakthrough therapy
• Specialty drugs
• Gilead Sciences
• Healthcare-associated infections
• Cyclopropanes
• Sofosbuvir
• Ledipasvir
• National Institute for Health and Care Excellence
• Hepatitis
• National Health Service

Patient Name:________________________________________ Date of Birth:__________________ Truvada® for Pre-Exposure Prophylaxis (PrEP) Medication Assistance Program Page 1 of 4

Source URL: start.truvada.com

• Medicine
• Health
• Gilead Sciences
• Pre-exposure prophylaxis
• Tenofovir/emtricitabine
• Medical prescription
• Emtricitabine
• Tenofovir disoproxil
• Health Insurance Portability and Accountability Act
• Personal health record

--------------------------------CONTRAINDICATIONS-----------------------------­ EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN

Source URL: www.accessdata.fda.gov

• Chemistry
• Gilead Sciences
• Medicine
• Clinical medicine
• Cyclopropanes
• Breakthrough therapy
• Combination drugs
• Organofluorides
• Sofosbuvir
• Ledipasvir
• Simeprevir
• Velpatasvir/sofosbuvir

GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations

Source URL: www.gilead.com

• Gilead Sciences
• Specialty drugs
• Pharmacology
• Business
• Biotechnology
• Combination drugs
• Breakthrough therapy
• Sofosbuvir
• Velpatasvir/sofosbuvir
• Gilead

Press release_Polyphor Ltd R&D Collaboration_Gilead August 10, 2016, 9 am CET Polyphor and Gilead establish R&D macrocycle drug discovery collaboration

Source URL: www.polyphor.com

• Health
• Clinical medicine
• Medicine
• Macrocycle
• Gilead Sciences
• Gilead
• Cystic fibrosis

Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction

Source URL: www.easl.eu

• Chemistry
• Clinical medicine
• Organic chemistry
• Breakthrough therapy
• Cyclopropanes
• Carbamates
• Gilead Sciences
• Imidazoles
• Sofosbuvir
• Simeprevir
• Ledipasvir
• Hepatitis C

T here is an exciting new development in HIV prevention that puts another tool in the hands of HIV-negative people. It’s called pre-exposure prophylaxis (PrEP), and we

Source URL: www.delawarehiv.org

• Prevention of HIV/AIDS
• HIV/AIDS
• Pre-exposure prophylaxis
• Tenofovir/emtricitabine
• Post-exposure prophylaxis
• HIV
• Sexually transmitted infection
• Gilead Sciences
• IPrEx
• HIV and pregnancy